Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 36 entries
Sorted by: Best Match Show Resources per page
Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial.

International journal of stroke : official journal of the International Stroke Society

Naidech AM, Grotta J, Elm J, Janis S, Dowlatshahi D, Toyoda K, Steiner T, Mayer SA, Khanolkar P, Denlinger J, Audebert HJ, Molina C, Khatri P, Sprigg N, Vagal A, Broderick JP.
PMID: 34427473
Int J Stroke. 2021 Sep 05;17474930211042700. doi: 10.1177/17474930211042700. Epub 2021 Sep 05.

INTRODUCTION: Intracerebral hemorrhage is the deadliest form of stroke. Hematoma expansion, growth of the hematoma between the baseline computed tomography scan and a follow-up computed tomography scan at 24 ± 6 h, predicts long-term disability or death. Recombinant factor...

Cite
Naidech AM, Grotta J, Elm J, et al. Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. Int J Stroke. 2021;17474930211042700doi: 10.1177/17474930211042700.
Naidech, A. M., Grotta, J., Elm, J., Janis, S., Dowlatshahi, D., Toyoda, K., Steiner, T., Mayer, S. A., Khanolkar, P., Denlinger, J., Audebert, H. J., Molina, C., Khatri, P., Sprigg, N., Vagal, A., & Broderick, J. P. (2021). Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. International journal of stroke : official journal of the International Stroke Society, 17474930211042700. https://doi.org/10.1177/17474930211042700
Naidech, Andrew M, et al. "Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial." International journal of stroke : official journal of the International Stroke Society vol. (2021): 17474930211042700. doi: https://doi.org/10.1177/17474930211042700
Naidech AM, Grotta J, Elm J, Janis S, Dowlatshahi D, Toyoda K, Steiner T, Mayer SA, Khanolkar P, Denlinger J, Audebert HJ, Molina C, Khatri P, Sprigg N, Vagal A, Broderick JP. Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. Int J Stroke. 2021 Sep 05;17474930211042700. doi: 10.1177/17474930211042700. Epub 2021 Sep 05. PMID: 34427473.
Copy Download .nbib Format: NLM
Mechanisms of Immunothrombosis by SARS-CoV-2.

Biomolecules

Hernández-Huerta MT, Pérez-Santiago AD, Pérez-Campos Mayoral L, Sánchez Navarro LM, Rodal Canales FJ, Majluf-Cruz A, Matias-Cervantes CA, Pérez-Campos Mayoral E, Romero Díaz C, Mayoral-Andrade G, Martínez Cruz M, Luna Ángel J, Pérez-Campos E.
PMID: 34827548
Biomolecules. 2021 Oct 20;11(11). doi: 10.3390/biom11111550.

SARS-CoV-2 contains certain molecules that are related to the presence of immunothrombosis. Here, we review the pathogen and damage-associated molecular patterns. We also study the imbalance of different molecules participating in immunothrombosis, such as tissue factor, factors of the...

Cite
Hernández-Huerta MT, Pérez-Santiago AD, Pérez-Campos Mayoral L, et al. Mechanisms of Immunothrombosis by SARS-CoV-2. Biomolecules. 2021;11(11)doi: 10.3390/biom11111550.
Hernández-Huerta, M. T., Pérez-Santiago, A. D., Pérez-Campos Mayoral, L., Sánchez Navarro, L. M., Rodal Canales, F. J., Majluf-Cruz, A., Matias-Cervantes, C. A., Pérez-Campos Mayoral, E., Romero Díaz, C., Mayoral-Andrade, G., Martínez Cruz, M., Luna Ángel, J., & Pérez-Campos, E. (2021). Mechanisms of Immunothrombosis by SARS-CoV-2. Biomolecules, 11(11), . https://doi.org/10.3390/biom11111550
Hernández-Huerta, María Teresa, et al. "Mechanisms of Immunothrombosis by SARS-CoV-2." Biomolecules vol. 11,11 (2021). doi: https://doi.org/10.3390/biom11111550
Hernández-Huerta MT, Pérez-Santiago AD, Pérez-Campos Mayoral L, Sánchez Navarro LM, Rodal Canales FJ, Majluf-Cruz A, Matias-Cervantes CA, Pérez-Campos Mayoral E, Romero Díaz C, Mayoral-Andrade G, Martínez Cruz M, Luna Ángel J, Pérez-Campos E. Mechanisms of Immunothrombosis by SARS-CoV-2. Biomolecules. 2021 Oct 20;11(11). doi: 10.3390/biom11111550. PMID: 34827548; PMCID: PMC8615366.
Copy Download .nbib Format: NLM
Prevention of venous thromboembolism, recurrent stroke, and other vascular events after acute ischemic stroke: the role of low-molecular-weight heparin and antiplatelet therapy.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

Sherman DG.
PMID: 17904084
J Stroke Cerebrovasc Dis. 2006 Nov-Dec;15(6):250-9. doi: 10.1016/j.jstrokecerebrovasdis.2006.06.001.

Patients with stroke or transient ischemic attacks (TIAs) are at increased risk of vascular events, such as recurrent stroke or venous thromboembolism (VTE), and thus the secondary prevention of such events is an important element of managing these patients....

Cite
Sherman DG. Prevention of venous thromboembolism, recurrent stroke, and other vascular events after acute ischemic stroke: the role of low-molecular-weight heparin and antiplatelet therapy. J Stroke Cerebrovasc Dis. 2006;15(6):250-9doi: 10.1016/j.jstrokecerebrovasdis.2006.06.001.
Sherman, D. G. (2006). Prevention of venous thromboembolism, recurrent stroke, and other vascular events after acute ischemic stroke: the role of low-molecular-weight heparin and antiplatelet therapy. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 15(6), 250-9. https://doi.org/10.1016/j.jstrokecerebrovasdis.2006.06.001
Sherman, David G. "Prevention of venous thromboembolism, recurrent stroke, and other vascular events after acute ischemic stroke: the role of low-molecular-weight heparin and antiplatelet therapy." Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association vol. 15,6 (2006): 250-9. doi: https://doi.org/10.1016/j.jstrokecerebrovasdis.2006.06.001
Sherman DG. Prevention of venous thromboembolism, recurrent stroke, and other vascular events after acute ischemic stroke: the role of low-molecular-weight heparin and antiplatelet therapy. J Stroke Cerebrovasc Dis. 2006 Nov-Dec;15(6):250-9. doi: 10.1016/j.jstrokecerebrovasdis.2006.06.001. PMID: 17904084.
Copy Download .nbib Format: NLM
Emerging anticoagulant and thrombolytic drugs.

Expert opinion on emerging drugs

Iqbal O, Aziz S, Hoppensteadt DA, Ahmad S, Walenga JM, Bakhos M, Fareed J.
PMID: 15989500
Expert Opin Emerg Drugs. 2001 Apr;6(1):111-35. doi: 10.1517/14728214.6.1.111.

Since its discovery, heparin has been used intensely as an anticoagulant for several medical and surgical indications. However, efforts are in progress to replace heparin because of its serious complications, such as intraoperative and postoperative bleeding, osteoporosis, alopecia, heparin...

Cite
Iqbal O, Aziz S, Hoppensteadt DA, et al. Emerging anticoagulant and thrombolytic drugs. Expert Opin Emerg Drugs. 2001;6(1):111-35doi: 10.1517/14728214.6.1.111.
Iqbal, O., Aziz, S., Hoppensteadt, D. A., Ahmad, S., Walenga, J. M., Bakhos, M., & Fareed, J. (2001). Emerging anticoagulant and thrombolytic drugs. Expert opinion on emerging drugs, 6(1), 111-35. https://doi.org/10.1517/14728214.6.1.111
Iqbal, O, et al. "Emerging anticoagulant and thrombolytic drugs." Expert opinion on emerging drugs vol. 6,1 (2001): 111-35. doi: https://doi.org/10.1517/14728214.6.1.111
Iqbal O, Aziz S, Hoppensteadt DA, Ahmad S, Walenga JM, Bakhos M, Fareed J. Emerging anticoagulant and thrombolytic drugs. Expert Opin Emerg Drugs. 2001 Apr;6(1):111-35. doi: 10.1517/14728214.6.1.111. PMID: 15989500.
Copy Download .nbib Format: NLM
Interactions between heparinoids and alcohol dehydrogenase.

Biochemistry and molecular biology international

Paulíková H, Valusová E, Antalík M.
PMID: 19856282
Biochem Mol Biol Int. 1997 Jul;42(4):667-76. doi: 10.1080/15216549700203081.

The interaction between polysulfated polysaecharides (low-molecular-weight heparin LMWH, dextran sulfate DS and pentosan sulfate PS) and yeast alcohol dehydrogenase (YADH) was investigated. The fluorescence and UV spectra of YADH after adding the tested polysaccharides have confirmed the interaction between...

Cite
Paulíková H, Valusová E, Antalík M. Interactions between heparinoids and alcohol dehydrogenase. Biochem Mol Biol Int. 1997;42(4):667-76doi: 10.1080/15216549700203081.
Paulíková, H., Valusová, E., & Antalík, M. (1997). Interactions between heparinoids and alcohol dehydrogenase. Biochemistry and molecular biology international, 42(4), 667-76. https://doi.org/10.1080/15216549700203081
Paulíková, H, et al. "Interactions between heparinoids and alcohol dehydrogenase." Biochemistry and molecular biology international vol. 42,4 (1997): 667-76. doi: https://doi.org/10.1080/15216549700203081
Paulíková H, Valusová E, Antalík M. Interactions between heparinoids and alcohol dehydrogenase. Biochem Mol Biol Int. 1997 Jul;42(4):667-76. doi: 10.1080/15216549700203081. PMID: 19856282.
Copy Download .nbib Format: NLM
Medical management of patients with brain tumors.

Current treatment options in neurology

Pruitt AA.
PMID: 21557041
Curr Treat Options Neurol. 2011 Aug;13(4):413-26. doi: 10.1007/s11940-011-0132-y.

OPINION STATEMENT: Patients with brain tumors require meticulous attention to medical issues resulting from their disease or its therapy. The following specific issues are the ones most frequently arising in the purview of neurologists: (1) Vasogenic edema: Corticosteroids should...

Cite
Pruitt AA. Medical management of patients with brain tumors. Curr Treat Options Neurol. 2011;13(4):413-26doi: 10.1007/s11940-011-0132-y.
Pruitt, A. A. (2011). Medical management of patients with brain tumors. Current treatment options in neurology, 13(4), 413-26. https://doi.org/10.1007/s11940-011-0132-y
Pruitt, Amy A. "Medical management of patients with brain tumors." Current treatment options in neurology vol. 13,4 (2011): 413-26. doi: https://doi.org/10.1007/s11940-011-0132-y
Pruitt AA. Medical management of patients with brain tumors. Curr Treat Options Neurol. 2011 Aug;13(4):413-26. doi: 10.1007/s11940-011-0132-y. PMID: 21557041.
Copy Download .nbib Format: NLM
European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke.

European stroke journal

Dennis M, Caso V, Kappelle LJ, Pavlovic A, Sandercock P.
PMID: 31008263
Eur Stroke J. 2016 Mar;1(1):6-19. doi: 10.1177/2396987316628384. Epub 2016 Mar 01.

BACKGROUND: Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism is a frequent complication in immobile patients with acute ischemic stroke. This guideline document presents the European Stroke Organisation guidelines for the prophylaxis of VTE in immobile...

Cite
Dennis M, Caso V, Kappelle LJ, et al. European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke. Eur Stroke J. 2016;1(1):6-19doi: 10.1177/2396987316628384.
Dennis, M., Caso, V., Kappelle, L. J., Pavlovic, A., Sandercock, P. (2016). European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke. European stroke journal, 1(1), 6-19. https://doi.org/10.1177/2396987316628384
Dennis, Martin, et al. "European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke." European stroke journal vol. 1,1 (2016): 6-19. doi: https://doi.org/10.1177/2396987316628384
Dennis M, Caso V, Kappelle LJ, Pavlovic A, Sandercock P. European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke. Eur Stroke J. 2016 Mar;1(1):6-19. doi: 10.1177/2396987316628384. Epub 2016 Mar 01. PMID: 31008263; PMCID: PMC6301216.
Copy Download .nbib Format: NLM
Chronic Venous Insufficiency.

Current treatment options in cardiovascular medicine

Schainfeld RM.
PMID: 12686008
Curr Treat Options Cardiovasc Med. 2003 Apr;5(2):109-119. doi: 10.1007/s11936-003-0019-7.

Patients with chronic venous insufficiency arguably have been relegated to a standard of care that is lower than that for those with the more appealing entity of peripheral arterial disease. Fortunately, the collaboration of an expanding group of clinicians...

Cite
Schainfeld RM. Chronic Venous Insufficiency. Curr Treat Options Cardiovasc Med. 2003;5(2):109-119doi: 10.1007/s11936-003-0019-7.
Schainfeld, R. M. (2003). Chronic Venous Insufficiency. Current treatment options in cardiovascular medicine, 5(2), 109-119. https://doi.org/10.1007/s11936-003-0019-7
Schainfeld, Robert M.. "Chronic Venous Insufficiency." Current treatment options in cardiovascular medicine vol. 5,2 (2003): 109-119. doi: https://doi.org/10.1007/s11936-003-0019-7
Schainfeld RM. Chronic Venous Insufficiency. Curr Treat Options Cardiovasc Med. 2003 Apr;5(2):109-119. doi: 10.1007/s11936-003-0019-7. PMID: 12686008.
Copy Download .nbib Format: NLM
Low molecular weight heparin in acute stroke.

Expert opinion on investigational drugs

Bath PM.
PMID: 15992034
Expert Opin Investig Drugs. 1998 Aug;7(8):1323-30. doi: 10.1517/13543784.7.8.1323.

Potential therapeutic strategies in acute ischaemic stroke include reperfusion, prevention of thrombus extension and rethrombosis and neuroprotection. Heparins inhibit thrombin and factor X and therefore may have useful effects on arterial and venous thrombosis; they are effective in the...

Cite
Bath PM. Low molecular weight heparin in acute stroke. Expert Opin Investig Drugs. 1998;7(8):1323-30doi: 10.1517/13543784.7.8.1323.
Bath, P. M. (1998). Low molecular weight heparin in acute stroke. Expert opinion on investigational drugs, 7(8), 1323-30. https://doi.org/10.1517/13543784.7.8.1323
Bath, P M. "Low molecular weight heparin in acute stroke." Expert opinion on investigational drugs vol. 7,8 (1998): 1323-30. doi: https://doi.org/10.1517/13543784.7.8.1323
Bath PM. Low molecular weight heparin in acute stroke. Expert Opin Investig Drugs. 1998 Aug;7(8):1323-30. doi: 10.1517/13543784.7.8.1323. PMID: 15992034.
Copy Download .nbib Format: NLM
Heparin-induced thrombocytopenia during renal replacement therapy.

Hemodialysis international. International Symposium on Home Hemodialysis

Davenport A.
PMID: 19379430
Hemodial Int. 2004 Jul 01;8(3):295-303. doi: 10.1111/j.1492-7535.2004.01108.x.

There is increasing awareness that antibodies to heparin/platelet factor 4 complex can develop in both those with acute renal failure treated with continuous forms of renal replacement therapy and, to a lesser extent, regular hemodialysis patients. Clinical manifestations include...

Cite
Davenport A. Heparin-induced thrombocytopenia during renal replacement therapy. Hemodial Int. 2004;8(3):295-303doi: 10.1111/j.1492-7535.2004.01108.x.
Davenport, A. (2004). Heparin-induced thrombocytopenia during renal replacement therapy. Hemodialysis international. International Symposium on Home Hemodialysis, 8(3), 295-303. https://doi.org/10.1111/j.1492-7535.2004.01108.x
Davenport, Andrew. "Heparin-induced thrombocytopenia during renal replacement therapy." Hemodialysis international. International Symposium on Home Hemodialysis vol. 8,3 (2004): 295-303. doi: https://doi.org/10.1111/j.1492-7535.2004.01108.x
Davenport A. Heparin-induced thrombocytopenia during renal replacement therapy. Hemodial Int. 2004 Jul 01;8(3):295-303. doi: 10.1111/j.1492-7535.2004.01108.x. PMID: 19379430.
Copy Download .nbib Format: NLM
Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing.

The Journal of pediatrics

Avila L, Amiri N, Yenson P, Khan S, Zavareh ZT, Chan AKC, Williams S, Brandão LR.
PMID: 32640269
J Pediatr. 2020 Nov;226:167-172.e2. doi: 10.1016/j.jpeds.2020.06.081. Epub 2020 Jul 05.

OBJECTIVES: To determine the applicability of the 4Ts score and the Heparin-Induced Thrombocytopenia (HIT) Expert Probability (HEP) score in children with suspected HIT and to estimate the number of children potentially at risk of HIT.STUDY DESIGN: We retrospectively estimated...

Cite
Avila L, Amiri N, Yenson P, et al. Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing. J Pediatr. 2020;226:167-172.e2doi: 10.1016/j.jpeds.2020.06.081.
Avila, L., Amiri, N., Yenson, P., Khan, S., Zavareh, Z. T., Chan, A. K. C., Williams, S., & Brandão, L. R. (2020). Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing. The Journal of pediatrics, 226167-172.e2. https://doi.org/10.1016/j.jpeds.2020.06.081
Avila, Laura, et al. "Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing." The Journal of pediatrics vol. 226 (2020): 167-172.e2. doi: https://doi.org/10.1016/j.jpeds.2020.06.081
Avila L, Amiri N, Yenson P, Khan S, Zavareh ZT, Chan AKC, Williams S, Brandão LR. Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing. J Pediatr. 2020 Nov;226:167-172.e2. doi: 10.1016/j.jpeds.2020.06.081. Epub 2020 Jul 05. PMID: 32640269.
Copy Download .nbib Format: NLM
The heparin-like activities of negatively charged derivatives of low-molecular-weight polymannuronate and polyguluronate.

Carbohydrate polymers

Li Q, Zeng Y, Wang L, Guan H, Li C, Zhang L.
PMID: 27702517
Carbohydr Polym. 2017 Jan 02;155:313-320. doi: 10.1016/j.carbpol.2016.08.084. Epub 2016 Aug 28.

A series of low-molecular-weight polymannuronate (LPM) and polyguluronate (LPG) polyanionic derivatives, including LPM/LPG phosphate (LPMP/LPGP), LPM/LPG H-phosphonate (LPMHP/LPGHP) and LPM/LPG sulfate (LPMS/LPGS), were prepared as heparinoids by chemical modification of LPM and LPG. The structures and characteristics of LPM,...

Cite
Li Q, Zeng Y, Wang L, et al. The heparin-like activities of negatively charged derivatives of low-molecular-weight polymannuronate and polyguluronate. Carbohydr Polym. 2016;155:313-320doi: 10.1016/j.carbpol.2016.08.084.
Li, Q., Zeng, Y., Wang, L., Guan, H., Li, C., & Zhang, L. (2017). The heparin-like activities of negatively charged derivatives of low-molecular-weight polymannuronate and polyguluronate. Carbohydrate polymers, 155313-320. https://doi.org/10.1016/j.carbpol.2016.08.084
Li, Quancai, et al. "The heparin-like activities of negatively charged derivatives of low-molecular-weight polymannuronate and polyguluronate." Carbohydrate polymers vol. 155 (2017): 313-320. doi: https://doi.org/10.1016/j.carbpol.2016.08.084
Li Q, Zeng Y, Wang L, Guan H, Li C, Zhang L. The heparin-like activities of negatively charged derivatives of low-molecular-weight polymannuronate and polyguluronate. Carbohydr Polym. 2017 Jan 02;155:313-320. doi: 10.1016/j.carbpol.2016.08.084. Epub 2016 Aug 28. PMID: 27702517.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 36 entries